Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress
March 23, 2022 08:00 ET
|
Ventyx Biosciences, Inc.
Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for our oral, selective NLRP3 inhibitor, VTX2735, expected in Q2 2022 Phase 2 trial of...
Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference
March 07, 2022 08:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new...
Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis
December 06, 2021 08:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new...
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
November 19, 2021 08:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new...
Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update
November 17, 2021 16:11 ET
|
Ventyx Biosciences, Inc.
Wholly-owned pipeline with three clinical-stage programs targeting significant inflammatory and immunology disease markets Dosing initiated in a multiple-ascending dose (MAD) Phase 1 trial for...
Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 25, 2021 16:58 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients...
Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering
October 20, 2021 20:38 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients...
Ventyx Biosciences Announces Key Appointments and Closing of $51.0 Million Series B Convertible Preferred Stock Financing Round
September 20, 2021 05:00 ET
|
Ventyx Biosciences, Inc.
Drs. Sheila Gujrathi (Executive Chair), Jörn Drappa (Chief Medical Officer) and Luisa Salter-Cid (Chair of the Scientific Advisory Board) bring decades of development experience in autoimmune...